Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04826991 · ClinicalTrials.gov registry record · NA

Wells and Enteric Disease Transmission

A NA study of Diarrhea and Respiratory Viral Infection, sponsored by Temple University.

Active
Registry status
NA
Development phase
908
Enrollment target
1
Study location

NCT04826991: Active NA study of Diarrhea and Respiratory Viral Infection, sponsored by Temple University.

NCT04826991 is a NA study of Diarrhea and Respiratory Viral Infection that is active but no longer recruiting, run by Temple University. The registered enrollment target is 908 participants, above the 119-participant average among 24 other Diarrhea trials with a reported enrollment target (663% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04826991, a NA study of Diarrhea and Respiratory Viral Infection, is active but no longer recruiting, sponsored by Temple University.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
908 participants
Enrollment target
1
Study location

Study Summary

Approximately 40 million people in the US are served by private, and frequently untreated, wells. Our best estimate is that 1.3 million cases of gastrointestinal illnesses (GI) per year are attributed to consuming water from untreated private wells in the US, but in reality, there are no robust epidemiological data that can be used to estimate cases of GI attributable to these sources. We propose the first randomized controlled trial (RCT) to estimate the burden of GI associated with private well water. We will test if household treatment of private well water by ultraviolet light (UV) vs. sham (inactive UV device) decreases the incidence of GI in children under 5. We will also examine the presence of viral, bacterial, and protozoan pathogens in stool and well water from participants. These data will fill a knowledge gap on sporadic GI associated with federally-unregulated private water supplies in the US.

Primary Outcome

The investigators will collect data on the presence of gastrointestinal illness symptoms through weekly text messages. Households that report symptoms through text messages will be directed to an online illness questionnaire to characterize the symptoms (type, incidence, severity, duration, etc.), as well as relevant exposure information such as recent travel, exposure to ill persons, etc. Incident gastrointestinal illness (GI) is defined by the reporting of a minimum of three episodes of diarrh

Interventions

  • DEVICE Active UV Device
  • DEVICE Inactive UV Device

Study Locations (1)

Pennsylvania

  • Temple University - Philadelphia

Trial Details

FieldValue
Enrollment Target 908 participants
Start Date 2021-07-01
Est. Completion 2027-08-31
Phase NA
Temple University

163 total trials

What the registry record for NCT04826991 still lists

NCT04826991 is an interventional study that assigns participants to a tested intervention. The registered 908 participants enrollment target is mid-sized for trials with a published cap, above the 119-participant average among 24 other Diarrhea trials with a reported enrollment target (663% higher).

The record links to 4 conditions, with Diarrhea appearing as the primary indexed condition, and to 2 interventions - of which Active UV Device is the first listed.

NCT04826991 reports a single indexed study location in Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT04826991 about?

NCT04826991 is a clinical study titled "Wells and Enteric Disease Transmission". Approximately 40 million people in the US are served by private, and frequently untreated, wells. Our best estimate is that 1.3 million cases of gastrointestinal illnesses (GI) per year are attributed to consuming water from untreated private wells in the US, but in reality, there are no robust epid...

What is the current status of trial NCT04826991?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 908 participants. The study started on 2021-07-01. Estimated completion is 2027-08-31.

What conditions does trial NCT04826991 study?

This clinical trial studies the following conditions: Diarrhea, Respiratory Viral Infection, Gastrointestinal Infection, Waterborne Diseases.

What interventions are being tested in trial NCT04826991?

The interventions under investigation include: Active UV Device (DEVICE), Inactive UV Device (DEVICE).

Who is sponsoring clinical trial NCT04826991?

This trial is sponsored by Temple University, which has 163 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04826991 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diarrhea

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04826991's enrollment target sits among peer trials

908 1st of 24 higher than 24 of 24 other Diarrhea trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diarrhea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05658497 · 908 participants

    Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

  • NCT06216548 · 909 participants · NA

    E-PRIME For Children With Medical Complexity

  • NCT06131840 · 914 participants · Phase 1

    A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

  • NCT05769777 · 901 participants · Phase 2

    Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04826991, the US trial registry maintained by the National Library of Medicine. NCT04826991 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.